Plasma Therapy of COVID-19 in Severely Ill Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

223

Participants

Timeline

Start Date

April 21, 2020

Primary Completion Date

December 30, 2020

Study Completion Date

December 30, 2020

Conditions
SARS-CoV-2 Infection
Interventions
BIOLOGICAL

Convalescent Plasma (anti-SARS-CoV-2 plasma)

Convalescent Plasma that contains antibody titers against SARS-CoV-2

BIOLOGICAL

Non-convalescent Plasma (control plasma)

Non-convalescent plasma (does not contain antibody titers against SARS-CoV-2)

Trial Locations (4)

10032

Columbia University Irving Medical Center/NYP, New York

Unknown

Hospital Federal dos Servidores do Estado, Rio de Janeiro

Hospital Geral de Nova Iguaçu, Rio de Janeiro

Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro

All Listed Sponsors
collaborator

New York Blood Center

OTHER

collaborator

Amazon, Inc.

INDUSTRY

lead

Max O'Donnell

OTHER

NCT04359810 - Plasma Therapy of COVID-19 in Severely Ill Patients | Biotech Hunter | Biotech Hunter